Sector: MedicalAlkermes, Inc. (NASDAQ: ALKS)
Headlines
- Alkermes Reports Second Quarter Fiscal 2010 Financial Results
Nov 05, 2009 04:00 PM | ALKS, JNJ
- Alkermes' Corporate Presentation to be Webcast at the Credit Suisse Healthcare Conference
Nov 04, 2009 04:00 PM | ALKS
- Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2010
Oct 29, 2009 04:00 PM | ALKS
- Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 37 for the Treatment of Opioid-Induced Constipation
Oct 27, 2009 08:30 AM | ALKS, RX
- Alkermes Announces Positive Results From Two Clinical Trials of ALKS 33
Oct 13, 2009 08:01 AM | ALKS
- Stock Futures Drop, Improve to Trade Mixed After Surprise Slide in Durable Goods Orders - Airlines Upgraded, RIMM Warns
Sep 25, 2009 09:15 AM | ALKS, AMR, CAL, LCC, PALM, RIMM
- Alkermes Announces Amylin and Lilly Will Present More than 20 Studies for Exenatide at EASD 2009
Sep 24, 2009 08:05 AM | ALKS, AMLN, LLY
- Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
Sep 24, 2009 08:02 AM | ALKS, AMLN, LLY
- Alkermes Chairman Richard Pops to Resume Role of CEO
Sep 11, 2009 09:00 AM | ALKS
- Alkermes' Corporate Presentation to be Webcast at the BioCentury NewsMakers Conference
Sep 09, 2009 04:00 PM | ALKS
- RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on ALV, CLS, VIT, TKC, CRK and ALKS
Oct 13, 2009 08:12 AM | ALKS, ALV, CLS, CRK, TKC, VIT
- Alkermes Reports First Quarter Fiscal 2010 Financial Results
Aug 06, 2009 04:04 PM | ALKS
- Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2010
Jul 30, 2009 04:05 PM | ALKS
- Alkermes’ Corporate Presentation to be Webcast at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
Jul 29, 2009 04:04 PM | ALKS
- BenchmarkJournal.Com Free Analyst Review for ITUB, APWR, CHRS, FMBI, ALKS and HANS
Jul 22, 2009 10:24 AM | ALKS, APWR, CHRS, FMBI, HANS
- Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
Jul 20, 2009 04:15 PM | ALKS, AMLN, LLY
- Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus® in Head-to-Head DURATION-3 Study
Jul 20, 2009 04:07 PM | ALKS
- New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
Jul 07, 2009 04:05 PM | ALKS, AMLN, LLY
- Alkermes' Corporate Presentation to be Webcast at the Jefferies & Company 3rd Annual Healthcare Conference
Jun 10, 2009 04:03 PM | ALKS
- Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control with Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
Jun 07, 2009 09:16 AM | ALKS
- Form 4 ALKERMES INC For: Nov 05 Filed by: BIBERSTEIN KATHRYN L (10K)
Nov 06, 2009 02:06 PM
- Form 4 ALKERMES INC For: Oct 06 Filed by: WALL MICHAEL A (10K)
Oct 08, 2009 05:46 PM
- Form 4 ALKERMES INC For: Oct 06 Filed by: SKALETSKY MARK B (10K)
Oct 08, 2009 05:43 PM
- Form 4 ALKERMES INC For: Oct 06 Filed by: RICH ALEXANDER (10K)
Oct 08, 2009 05:40 PM
- Form 4 ALKERMES INC For: Oct 06 Filed by: MITCHELL PAUL J (10K)
Oct 08, 2009 05:34 PM
- Form 4 ALKERMES INC For: Oct 06 Filed by: HENWOOD GERALDINE (10K)
Oct 08, 2009 05:29 PM
- Form 4 ALKERMES INC For: Oct 06 Filed by: BREYER ROBERT A (10K)
Oct 08, 2009 05:24 PM
- Form 4 ALKERMES INC For: Oct 06 Filed by: BLOOM FLOYD E (10K)
Oct 08, 2009 05:18 PM
- Form 4 ALKERMES INC For: Oct 06 Filed by: ANSTICE DAVID W (10K)
Oct 08, 2009 05:18 PM
- Form 4 ALKERMES INC For: Jun 29 Filed by: Ehrich Elliot (10K)
Jun 30, 2009 03:22 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
ALKS
|
Compare to S&P
|
| YTD |
-25.16 %
|
-34.77 %
|
| 4 Weeks |
-9.43 %
|
-10.39 %
|
| 12 Weeks |
-24.45 %
|
-26.33 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 21.43 %
|
|
EPS Growth in Last Year: -135.48 %
|
|
Sales Growth in Last Quarter: 8.25 %
|
|
Sales Growth in Last Quarter: -40.62 %
|
|
